Benin poised to join elite group of francophone nations with who certification
The Beninese Agency for Medicines and Health Products (ABMed) has just completed a rigorous four-day evaluation by a World Health Organization (WHO) expert panel from July 6 to 9, 2026. This unprecedented assessment scrutinized the country’s pharmaceutical regulatory framework, offering a critical milestone in its decade-long journey toward health sector transformation.
Comprehensive health system evaluation unfolds in Cotonou
A high-level delegation of eight international WHO specialists conducted an exhaustive review of Benin’s pharmaceutical landscape. Every facet of the ABMed’s operations came under scrutiny—from drug licensing and market surveillance to pharmacovigilance and clinical trial oversight. The mission’s objective was clear: to measure how closely Benin’s regulatory processes align with the world’s most stringent health safety benchmarks.
The findings, unveiled in Cotonou on July 9, reveal remarkable progress. The evaluation confirmed substantial improvements, signaling that Benin is on the verge of securing a globally recognized pharmaceutical governance status.
Niveau de Maturité 3: A benchmark for pharmaceutical excellence
The WHO’s Niveau de Maturité 3 (NM3) represents the gold standard in pharmaceutical regulation. Countries achieving this status operate robust, fully integrated drug control systems capable of overseeing their entire pharmaceutical supply chain.
For Benin, reaching NM3 would mean more than just regulatory compliance—it would guarantee citizens access to safe, high-quality medicines while dismantling the shadow market of counterfeit drugs. This certification also enhances international credibility, attracting investment and unlocking new export opportunities for local manufacturers.
From 2017 reforms to global recognition
Health Minister Professor Benjamin Hounkpatin presided over the evaluation’s conclusion, expressing deep satisfaction with the WHO’s preliminary findings. In a speech to ABMed officials, he highlighted the transformative impact of reforms launched in 2017, which included:
- Establishing the autonomous ABMed to replace the former pharmacy directorate
- Strengthening legal frameworks to combat substandard and falsified medicines
- Implementing rigorous quality control across the pharmaceutical value chain
The Minister reaffirmed the government’s unwavering commitment to supporting ABMed until the NM3 certification becomes official, calling it a national priority.
West Africa’s next pharmaceutical hub?
If the final WHO report validates Benin’s progress, the country will join Senegal as the second francophone nation in West Africa to achieve NM3 status. This achievement would position Benin as a regional leader in health governance, proving that African nations can achieve global standards through political will and technical excellence.
A new chapter for public health
July 2026’s WHO mission marks a historic turning point for Benin’s health sector. With promising indicators in hand, ABMed must now implement the remaining recommendations to secure its NM3 certification. This milestone demonstrates that patient safety and pharmaceutical sovereignty are not distant aspirations but tangible realities within reach.
